Immuneering Corp Stock In The News

IMRX Stock  USD 2.24  0.15  7.18%   
Our overall analysis of Immuneering Corp's news coverage and content from conventional and social sources shows investors' bearish mood towards Immuneering Corp. The specific impact of Immuneering Corp news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Immuneering Corp's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Immuneering Corp headlines in addition to utilizing other, more conventional financial analysis modules. Check out Immuneering Corp Backtesting and Immuneering Corp Hype Analysis.
For more information on how to buy Immuneering Stock please use our How to Invest in Immuneering Corp guide.

Immuneering Corp Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference
https://www.globenewswire.com/news-release/2023/11/20/2783587/0/en/Immuneering-to-Present-at-the-35th-Annual-Piper-Sandler-Healthcare-Conference.html
 Neutral
Macroaxis News: globenewswire.com
SHAREHOLDER ALERT: Kaskela Law LLC Annou...
https://www.globenewswire.com/news-release/2023/11/11/2778582/0/en/SHAREHOLDER-ALERT-Kaskela-Law-LLC-Announces-Investigation-of-Immuneering-Corporation-NASDAQ-IMRX-and-Encourages-Investors-to-Contact-the-Firm.html
 Bullish
Macroaxis News: globenewswire.com
Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates
https://www.globenewswire.com/news-release/2023/11/09/2777808/0/en/Immuneering-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Updates.html
 Neutral
Macroaxis News: globenewswire.com
Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference
https://www.globenewswire.com/news-release/2023/10/12/2759646/0/en/Immuneering-Presents-Preclinical-Data-Demonstrating-Encouraging-Anti-Tumor-Activity-for-IMM-1-104-and-IMM-6-415-at-AACR-NCI-EORTC-Conference.html
 Neutral
Macroaxis News: globenewswire.com
Immuneering to Present Preclinical Data ...
https://www.globenewswire.com/news-release/2023/10/04/2754930/0/en/Immuneering-to-Present-Preclinical-Data-on-IMM-1-104-and-IMM-6-415-at-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics.html
 Neutral
Macroaxis News: globenewswire.com
Immuneering to Present at the Morgan Stanley Healthcare Conference
https://www.globenewswire.com/news-release/2023/09/06/2738329/0/en/Immuneering-to-Present-at-the-Morgan-Stanley-Healthcare-Conference.html
 Neutral
Macroaxis News: globenewswire.com
Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates
https://www.globenewswire.com/news-release/2023/08/03/2718562/0/en/Immuneering-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Updates.html
 Neutral
Macroaxis News: globenewswire.com
Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors
https://www.globenewswire.com/news-release/2023/06/05/2681894/0/en/Immuneering-Completes-Dose-Escalation-in-the-IMM-1-104-Phase-1-Clinical-Trial-for-RAS-Mutant-Advanced-Solid-Tumors.html
 Neutral
Macroaxis News: globenewswire.com
Immuneering to Present at the Jefferies Healthcare Conference
https://www.globenewswire.com/news-release/2023/05/30/2678271/0/en/Immuneering-to-Present-at-the-Jefferies-Healthcare-Conference.html
 Neutral
Macroaxis News: globenewswire.com
Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates
https://www.globenewswire.com/news-release/2023/05/04/2662014/0/en/Immuneering-Reports-First-Quarter-2023-Financial-Results-and-Provides-Business-Updates.html
 Bullish

Immuneering Corp Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Immuneering and other traded companies coverage with news coverage. We help investors stay connected with Immuneering headlines for the 20th of October to make an informed investment decision based on correlating the impacts of news items on Immuneering Stock performance. Please note that trading solely based on the Immuneering Corp hype is not for everyone as timely availability and quick action are needed to avoid losses.
Immuneering Corp's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Immuneering Corp investors visualize upcoming and past events in order to time the market based on Immuneering Corp noise-free hype analysis.
Immuneering Corp stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Immuneering earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Immuneering Corp that are available to investors today. That information is available publicly through Immuneering media outlets and privately through word of mouth or via Immuneering internal channels. However, regardless of the origin, that massive amount of Immuneering data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Immuneering Corp news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Immuneering Corp relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Immuneering Corp's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Immuneering Corp alpha.

Immuneering Largest EPS Surprises

Earnings surprises can significantly impact Immuneering Corp's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-03-01
2023-12-31-0.47-0.52-0.0510 
2023-11-09
2023-09-30-0.49-0.430.0612 
2023-03-06
2022-12-31-0.58-0.50.0813 
2022-08-10
2022-06-30-0.52-0.440.0815 
2023-08-03
2023-06-30-0.53-0.430.118 
2021-11-09
2021-09-30-0.57-0.470.117 
View All Earnings Estimates

Immuneering Corp Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Immuneering Corp Stock. The global stock market is bullish. About 68% of major world exchanges and indexes are currently up. See today's market update for more information.
Yahoo News
15th of October 2024
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancr...
at finance.yahoo.com 
news
18th of September 2024
Immuneering Co. to Post FY2024 Earnings of Per Share, Chardan Capital Forecasts
at thelincolnianonline.com 
benzinga news
13th of September 2024
Why Is Nanocap Immuneering Stock Trading Higher On Friday
at benzinga.com 
Yahoo News
12th of September 2024
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Respon...
at finance.yahoo.com 
Simply Wall St News at Macroaxis
30th of August 2024
Companies Like Immuneering Could Be Quite Risky
at simplywall.st 
Google News at Macroaxis
19th of August 2024
Mizuho awaits key Phase 2a data likely to impact Immuneering stock - Investing.com
at news.google.com 
Yahoo News
6th of August 2024
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
at finance.yahoo.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immuneering Corp in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immuneering Corp's short interest history, or implied volatility extrapolated from Immuneering Corp options trading.

Additional Tools for Immuneering Stock Analysis

When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.